Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Leuk Lymphoma. 2019 Oct;60(10):2576-2579. doi: 10.1080/10428194.2019.1585837. Epub 2019 Apr 18.

Authors

Abi Vijenthira¹, Manjula Maganti², Vishal Kukreti³, John Kuruvilla³, Rodger Tiedemann³, Christine Chen³, Michael Crump³, Anca Prica³

Affiliations

¹ Postgraduate Medical Education, University of Toronto , Toronto , Canada.
² Department of Biostatistics, Princess Margaret Cancer Centre , Toronto , Canada.
³ Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.

PMID: 30997853
DOI: 10.1080/10428194.2019.1585837

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Lymphoma / drug therapy*
Lymphoma / pathology*
Molecular Targeted Therapy
Prognosis
Rituximab / administration & dosage
Rituximab / adverse effects
Rituximab / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Rituximab